KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Net Income (2016 - 2025)

Alnylam Pharmaceuticals' Net Income history spans 16 years, with the latest figure at $111.5 million for Q4 2025.

  • For Q4 2025, Net Income rose 233.17% year-over-year to $111.5 million; the TTM value through Dec 2025 reached $319.7 million, up 214.93%, while the annual FY2025 figure was $313.7 million, 212.79% up from the prior year.
  • Net Income reached $111.5 million in Q4 2025 per ALNY's latest filing, down from $292.7 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of $292.7 million in Q3 2025 to a low of -$405.9 million in Q3 2022.
  • Average Net Income over 5 years is -$119.1 million, with a median of -$156.0 million recorded in 2023.
  • The largest YoY upside for Net Income was 362.33% in 2025 against a maximum downside of 292.43% in 2025.
  • A 5-year view of Net Income shows it stood at -$258.5 million in 2021, then rose by 19.72% to -$207.5 million in 2022, then surged by 33.55% to -$137.9 million in 2023, then surged by 39.24% to -$83.8 million in 2024, then soared by 233.17% to $111.5 million in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Net Income are $111.5 million (Q4 2025), $292.7 million (Q3 2025), and -$66.3 million (Q2 2025).